bullish
Telix Pharmaceutical US ADS - Past Deal Record Hasn't Been Strong, but Fortune Could Be Turning
483 Views28 May 2024 06:45
Telix Pharmaceuticals (TLX AU) aims to raise at least US$100m in its US ADS listing. The bookrunners on the deal are Jefferies, Morgan Stanley, Truist Securities, and William Blair.
What is covered in the Full Insight:
- Deal Background
- Past Funding Deals
- Recent Performance and Deal Impact
- Upcoming Developments
- Analysts' Views and Valuation
Boomeranged on Thu, 6 Jun 2024 14:45
Telix Pharmaceuticals has launched its bookbuild to raise US$200m from its US ADR listing. Pricing is scheduled for 13th Jun 2024, after market close. The shares have continued to trade higher, and are now 15.9% higher than when we first published our note on the deal.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Tamboran Resources US Offering - Strong Recent Momentum but CDIs Have Been Volatile Since Listing21 Jun 2024
- Telix Pharmaceutical US ADS - Momentum Remains Strong, Offering Would Triple Its Cash Base12 Jun 2024
- Telix Pharmaceuticals (TLX AU): Accelerated US Growth in 1Q24; Two More US Launches Likely in 202418 Apr 2024
- Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?25 Jun 2018
- Autonomous Driving- The Tesla Delusion06 Apr 2018
x